

Trial record **1 of 3** for: Covid19 | Vaccine | BIONTECH [Lead] | PFIZER | Phase 3

[Previous Study](#) | [Return to List](#) | [Next Study](#)

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

A The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our [disclaimer](#) for details.

ClinicalTrials.gov Identifier: NCT04368728
Recruitment Status: Active, not recruiting
First Posted: April 30, 2020
Last Update Posted: February 10, 2021

Sponsor:
BioNTech SE

Collaborator:
Pfizer

Information provided by (Responsible Party):
BioNTech SE

[Study Details](#) | [Tabular View](#) | [No Results Posted](#) | [Disclaimer](#) | [How to Read a Study Record](#)

Study Description

Go to

Brief Summary:

This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals.
The study consists of 2 parts: Phase 1: to identify preferred vaccine candidate(s) and dose level(s); Phase 2/3: an expanded cohort and efficacy part.
The study will evaluate the safety, tolerability, and immunogenicity of 2 different SARS CoV 2 RNA vaccine candidates against COVID 19 and the efficacy of 1 candidate: